FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for STRATTERA (atomoxetine hydrochloride) filed by Eli Lilly and Company to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• STRATTERA (Atomoxetine hydrochloride)

Snippet

SUPPL AP for STRATTERA (ATOMOXETINE HYDROCHLORIDE)